Labiotech.eu

More News! 16 Nov 2022

Mineralys has positive topline results from trial evaluating treatment of hypertension

U.S.-based Mineralys Therapeutics, Inc., announced today (November 16) topline results from its phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily, met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood […]

November 16, 2022 - 4 minutesmins - By Liza Laws

Best in Biotech 16 Nov 2022

Six biotech stocks trading below cash right now

The biotech stock market is currently in a tough spot, with many companies facing suppressed valuations. We’ve listed six public companies trading with a market cap below their cash in hand. A range of factors are driving down company valuations in the public biotech market, such as soaring inflation, geopolitical instability and the threat of […]

November 16, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 16 Nov 2022

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Israeli company, Wilk, has today (November 16) announced the successful development of the world’s first yogurt developed with cell-cultured milk fat. The company is a developer of cell-cultured human and animal milk and milk components and this hybrid product has been validated by external laboratories, which Wilk says confirms it meets the necessary chemical and […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Bio-Rad Laboratories Inc. yesterday (November 15) announced the launch of its Pioneer Platform, a new antibody discovery service specifically designed to develop biologic candidates. The Pioneer Platform features a phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Ascletis’ monkeypox tablet receives IND approval from the FDA

A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision based on the available data, which was 800 mg ASC10 taken twice a day, and Ascletis can now go ahead with a phase 1b clinical […]

November 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Enzymes could be key to understanding ‘origin of DNA errors’

Enzymes, critical to controlling how cells replicate in the human body, could be the very ingredient that encourages DNA to spontaneously mutate – causing potentially permanent genetic errors, according to new research from the University of Surrey in the U.K. Using quantum chemical calculations, researchers from Surrey’s Quantum Biology Doctoral Training Centre have found that […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Growth in UK cell and gene therapy sector continues

The Cell and Gene Therapy Catapult (CGT Catapult) has published its ninth annual U.K. cell and gene therapy Good Manufacturing Practice (GMP) manufacturing report, showing continued growth in the advanced therapy medicinal products (ATMP) UK manufacturing sector. This growth is across industry and academia, showing how the sector is responding to the operationalization and skills […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Kadans Science Partner to develop new London life sciences innovation facility

Kadans Science Partner and Canary Wharf Group (CWG) are developing a new innovation facility in London, U.K., to provide access to fully-fitted laboratories and space for developing life science companies. Kadans Science Partner is converting levels four and five, totalling 38,000 sq ft, at the BREEAM Outstanding 20 Water Street, into flexible, fully serviced CL2 […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Immutep announces efti clinical results for non-small cell lung cancer

Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.4 million) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (DTIF). Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Aelis Farma has announced positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndrome, with AEF0217, its drug candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made […]

November 15, 2022 - 4 minutesmins - By Liza Laws

Ilya Pharma enrols first patient in diabetic foot ulcer study

More News! 15 Nov 2022

Destiny Pharma’s XF-73 dermal infection project advances to safety study

The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […]

November 15, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Mineralys has positive topline results from trial evaluating treatment of hypertension

Six biotech stocks trading below cash right now

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Ascletis’ monkeypox tablet receives IND approval from the FDA

Enzymes could be key to understanding ‘origin of DNA errors’

Growth in UK cell and gene therapy sector continues

Kadans Science Partner to develop new London life sciences innovation facility

Immutep announces efti clinical results for non-small cell lung cancer

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Destiny Pharma’s XF-73 dermal infection project advances to safety study

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!